NASDAQ · QURE
Healthcare · Biotechnology
$22.80
Up+$0.29 (+1.25%)
Updated Oct 6, 2026, 7:52 PM
SID Score
4.5/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · QURE
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 5, 2026
QURE closed at $22.80 after 20 trading sessions, down 50.09% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 5, 2026 | $22.28 | $23.24 | $21.37 | $22.80 | 3.04M |
| Oct 2, 2026 | $23.72 | $23.72 | $22.7101 | $23.46 | 1.95M |
| Oct 1, 2026 | $24.34 | $24.90 | $23.24 | $23.37 | 3.19M |
| Sep 30, 2026 | $25.07 | $26.68 | $24.01 | $24.16 | 7.44M |
| Sep 29, 2026 | $23.85 | $26.00 | $22.47 | $24.51 | 29.81M |
| Sep 28, 2026 | $37.65 | $39.665 | $37.18 | $39.11 | 1.85M |
| Sep 25, 2026 | $38.195 | $39.12 | $37.62 | $38.23 | 1.18M |
| Sep 24, 2026 | $42.42 | $42.87 | $36.82 | $38.32 | 4.24M |
| Sep 23, 2026 | $45.17 | $45.41 | $42.625 | $42.76 | 1.17M |
| Sep 22, 2026 | $44.50 | $45.80 | $44.47 | $45.28 | 1.15M |
| Sep 21, 2026 | $44.50 | $45.025 | $43.81 | $44.31 | 801.23K |
| Sep 18, 2026 | $44.40 | $44.52 | $43.56 | $44.00 | 2.1M |
| Sep 17, 2026 | $43.47 | $44.58 | $43.00 | $44.09 | 799.17K |
| Sep 16, 2026 | $43.40 | $43.73 | $41.67 | $42.49 | 1.47M |
| Sep 15, 2026 | $44.73 | $44.825 | $42.58 | $43.10 | 1.22M |
| Sep 14, 2026 | $44.27 | $45.75 | $44.05 | $44.93 | 709.63K |
| Sep 11, 2026 | $44.66 | $45.30 | $44.04 | $44.51 | 1.24M |
| Sep 10, 2026 | $45.68 | $45.82 | $44.40 | $44.47 | 923.24K |
| Sep 9, 2026 | $45.71 | $46.98 | $45.37 | $46.00 | 1.35M |
| Sep 8, 2026 | $43.375 | $46.25 | $43.05 | $45.68 | 1.4M |
The latest Smart Investors Daily articles mentioning QURE.
Company
Market Activity
Research & News
QURE research
Company profile and research snapshot.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 5, 2026 | Barclays | Equal-Weight | — |
| Oct 2, 2026 | RBC Capital | Outperform | — |
| Sep 30, 2026 | Goldman Sachs | Neutral | — |
| Sep 2, 2026 | William Blair | Outperform | — |
| Jul 30, 2026 | Wells Fargo | Overweight | — |
No generated briefing is available yet.
SeekingAlpha · Sep 29, 2026
uniQure N.V. (QURE) Discusses Additional Data from Phase I/II AMT-130 Study in Huntington's Disease Highlighting Disease Progression Slowing September 29,...
SeekingAlpha · Sep 29, 2026
2026-09-29. The following slide deck was published by uniQure N.V.
Benzinga · Sep 29, 2026
uniQure announced long-term trial results for its Huntington's gene therapy, showing slowed disease progression at 36 and 48 months.
Benzinga · Sep 29, 2026
~ In 12 high-dose patients at 48 months, both cUHDRS and TFC continued to demonstrate meaningful slowing of disease progression and clear dose-dependent response; the primary endpoint of cUHDRS showed 44% slowing of
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning QURE.
